Fortrea’s $45M Phase I Grab Is Your Vendor Continuity Problem Now
Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division reshapes Phase I site networks and vendor contracts for sponsors...
Fortrea's $45M acquisition of Worldwide Clinical Trials' early-phase division reshapes Phase I site networks and vendor contracts for sponsors...
Fortrea's $45M buy of Worldwide Clinical Trials' Early Phase Services unit means active sponsors face contract novation, lab method...
A CBC isn't covered because it's routine. It's covered because NCD 190.15 says when. Here's how citation-level MCAs survive...
Aprea's APR-1051 early signals are forcing a rapid site expansion—here's what the enrollment acceleration actually costs at the operational...
Boston Scientific's August 2026 cyberattack knocked out global IT and shipping. Here's what that means for sites running active...
A sponsor's mid-study clinical system migration lands on sites first: reconciliation work, documentation risk, and monitoring gaps nobody budgeted....
Merck and SCRI's Accelero™ collaboration targets community oncology enrollment, but the real test is whether 200+ sites can execute...
Curavit's acquisition of Lindus Health CRO assets combines 1,000+ global sites with DCT infrastructure—but site teams absorb the operational...
Curavit's acquisition of Lindus Health's CRO assets unifies 13,478 sites across 79 countries — but site teams will navigate...
Tufts CSDD puts 82x ROI on AI monitoring agents in Phase 3 oncology. Before sponsors restructure monitoring teams, sites...